US FDA approves Medtronic’s system for heart condition
FILE PHOTO: Medtronic Plc logo is seen displayed in this illustration taken, April 10, 2023. REUTERS/Dado Ruvic/Illustration/File Photo
MDT
+2.29%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
(Reuters) -Medtronic said on Wednesday that the U.S. Food and Drug Administration (FDA) had approved its system for a type of condition that can cause stroke or heart failure.
The system, PulseSelect Pulsed Field Ablation (PFA), is used for the treatment of atrial fibrillation (AF), a condition that is characterized by an irregular rhythm of the heart.
PFA is used for ablation procedures that treat AF using small burns or freezes to cause some scarring on the inside of the heart to help break up the electrical signals that cause irregular heartbeats.
Commercialization of the PFA system will start in early 2024, the company said.
